论文部分内容阅读
作者对比了静滴溶血栓药Alteplase加肝素与安慰剂加肝素治疗急性心肌梗塞(AMI)的疗效。 5013例AMI患者,于发病5小时内随机2514例接受静滴100mg A1teplase加肝素(治疗组),2499例接受安慰剂加肝素(对照组)。治疗组患者平均住院天数为7.7天,对照组7.9天。6个月时随访治疗组2508例,对照组2495例患者。治疗组中死亡261例(10.4%),对照组328例(13.1%),相对减少了21%(p=0.0026)。大多数死亡发生于已证实心肌梗塞者(治疗组12.6%,对照组17.1%,相对减少了26.3%)。治疗组2361例和对照组2300例幸存出院患者中,6个月时分别有108例(4.6%)与129例死亡,死于
The authors compared the efficacy of intravenous thrombolytic drugs Alteplase plus heparin with placebo plus heparin in the treatment of acute myocardial infarction (AMI). A total of 5013 patients with AMI were randomized to receive 2,51 intravenous infusion of 100 mg of A1teplase plus heparin (treatment group) within 5 hours of onset and 2499 to receive placebo plus heparin (control group). The average length of hospital stay in the treatment group was 7.7 days and in the control group 7.9 days. At 6 months, 2508 patients in the treatment group and 2495 patients in the control group were followed up. There were 261 deaths (10.4%) in the treatment group and 328 (13.1%) in the control group, a relative decrease of 21% (p = 0.0026). Most deaths occurred in confirmed myocardial infarction (12.6% in the treatment group, 17.1% in the control group, a relative reduction of 26.3%). Among 2361 patients in the treatment group and 2300 patients in the control group who survived discharge, 108 (4.6%) and 129 patients died at 6 months